Retinoblastoma widely expresses the ganglioside GD2 even in pre-treated chemo-refractory cases with MYCN amplification (105, 130, 131) (Figure 2), suggesting that anti-GD2 monoclonal antibodies may be effective. Here, MYCN is linked to retinoblastoma.